20:00 , Apr 26, 2019 |  BC Week In Review  |  Clinical News

Prothena sees potential path forward for amyloidosis candidate

Prothena said it will explore business development opportunities that could lead to further clinical investigation of amyloid light-chain (AL) amyloidosis candidate birtamimab (NEOD001) after post hoc analyses of the Phase III VITAL trial showed a...
19:20 , Jan 31, 2019 |  BC Extra  |  Company News

Alexion takes option to acquire Caelum's amyloidosis program

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) purchased an equity stake in Caelum Biosciences Inc. (New York, N.Y.) and an obtained an option to acquire the company, which is developing a mAb to treat amyloid light-chain (AL) amyloidosis....
03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with...
19:50 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

Prothena discontinues AL amyloidosis candidate

Prothena Corp. plc (NASDAQ:PRTA) discontinued development of amyloid light-chain (AL) amyloidosis candidate NEOD001. The company said the humanized mAb targeting amyloid missed the primary and secondary endpoints in the Phase IIb PRONTO trial, and an...
15:13 , Apr 23, 2018 |  BC Extra  |  Clinical News

Prothena plummets after amyloidosis failure

Prothena Corp. plc (NASDAQ:PRTA) sank $25.34 (69%) to $11.50 on Monday after it discontinued development of amyloid light-chain (AL) amyloidosis candidate NEOD001. The company said the humanized mAb targeting amyloid missed the primary and secondary...
21:01 , May 17, 2017 |  BC Week In Review  |  Clinical News

Prothena completes enrollment in Phase IIb amyloidosis trial

Prothena Corp. plc (NASDAQ:PRTA) said it completed enrollment of 129 patients with amyloid light-chain (AL) amyloidosis who had a hematologic response to previous treatment and have persistent cardiac dysfunction in the Phase IIb PRONTO trial...
22:38 , Mar 3, 2017 |  BC Extra  |  Financial News

Prothena raises $155.3M in follow-on

Antibody company Prothena Corp. plc (NASDAQ:PRTA) raised $155.3 million through the sale of 2.7 million shares at $57.50 in a follow-on underwritten by Cantor Fitzgerald. The price is a 4% discount to the company's close...
07:00 , May 16, 2016 |  BioCentury  |  Product Development

Drug development gets personal

In the drug development world, it's not uncommon for scientists to commit their entire careers to the pursuit of a single cure - with no guarantee of success. It's happening right now in the labs...
08:00 , Dec 7, 2015 |  BioCentury  |  Regulation

Action in amyloidosis

The Amyloidosis Research Consortium is following in the footsteps of another well-organized rare disease community by drafting a proposed FDA guidance that will reflect patients' priorities. The advocacy group also plans to qualify a cardiac...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Clinical News

NEOD001: Additional Phase I/II data

Data from 27 patients with AL amyloidosis and persistent organ dysfunction in an open-label, dose-escalation, U.S. Phase I/II trial showed that the recommended Phase II dose of IV NEOD001 was 24 mg/kg given every 28...